Abstract
Contrast induced nephropathy (CIN) is an iatrogenic form of acute kidney injury (AKI) with variable but growing prevalence secondary to increased need for contrast administration during medical investigations such as coronary angiography. The mechanism of CIN is complex and poorly understood but is believed to be secondary to renal medullary hypoxia secondary to direct tubular toxicity from the contrast media and vasoconstriction. N-acetylcysteine (NAC) an antioxidant and vasodilator, has shown promising results in early investigations but failed to demonstrate consistent results in subsequent clinical trials and their meta-analysis. In this review we aim to discuss pharmacological properties of NAC and appraise the literature regarding the use of NAC for the prevention of CIN after coronary angiography. Keywords: Acetylcysteine/therapeutic use, angiography/adverse effects, contrast media/adverse effects, humans, kidney diseases/chemically induced, kidney diseases/prevention & control.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
